Efficacy and safety of the angiotensin II receptor blocker losartan for hypertrophic cardiomyopathy: The INHERIT randomised, double-blind, placebo-controlled trial

The Lancet Diabetes and Endocrinology

Volumn 3, Issue 2, 2015, Pages 123-131

  Axelsson, Anna ^a,b   Iversen, Kasper ^a   Vejlstrup, Niels ^a   Ho, Carolyn ^c   Norsk, Jakob ^a   Langhoff, Lasse ^a   Ahtarovski, Kiril ^a   Corell, Pernille ^d   Havndrup, Ole ^d   Jensen, Morten ^a   Bundgaard, Henning ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b HARVARD MEDICAL SCHOOL   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d ROSKILDE HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; LOSARTAN; PLACEBO; ANGIOTENSIN 1 RECEPTOR ANTAGONIST;

ADULT; ANGIONEUROTIC EDEMA; ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; FEMALE; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HEART LEFT VENTRICLE OUTFLOW TRACT OBSTRUCTION; HEART MUSCLE FIBROSIS; HEART VOLUME; HUMAN; HYPERKALEMIA; HYPERTROPHIC CARDIOMYOPATHY; KIDNEY DISEASE; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIAL; SUDDEN CARDIAC DEATH; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; CARDIOMYOPATHY, HYPERTROPHIC; FIBROSIS; FOLLOW UP; HEART VENTRICLE; HYPERTROPHY, LEFT VENTRICULAR; MIDDLE AGED; PATHOLOGY;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; CARDIOMYOPATHY, HYPERTROPHIC; DOUBLE-BLIND METHOD; FEMALE; FIBROSIS; FOLLOW-UP STUDIES; HEART VENTRICLES; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; LOSARTAN; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 84921439070     PISSN: 22138587     EISSN: 22138595     Source Type: Journal    
DOI: 10.1016/S2213-8587(14)70241-4     Document Type: Article

References (35)

1. Maron BJ, Gardin JM, Flack JM, Gidding SS, Kurosaki TT, Bild DE Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA Study. Coronary Artery Risk Development in (Young) Adults. Circulation 1995, 92:785-789.
2. Konno T, Chang S, Seidman JG, Seidman CE Genetics of hypertrophic cardiomyopathy. Curr Opin Cardiol 2010, 25:205-209.
3. Andersen PS, Havndrup O, Hougs L, et al. Diagnostic yield, interpretation, and clinical utility of mutation screening of sarcomere encoding genes in Danish hypertrophic cardiomyopathy patients and relatives. Hum Mutat 2009, 30:363-370.
4. Morita H, Rehm HL, Menesses A, et al. Shared genetic causes of cardiac hypertrophy in children and adults. N Engl J Med 2008, 358:1899-1908.
5. Olivotto I, Girolami F, Ackerman MJ, et al. Myofilament protein gene mutation screening and outcome of patients with hypertrophic cardiomyopathy. Mayo Clin Proc 2008, 83:630-638.
6. Force T, Bonow RO, Houser SR, et al. Research priorities in hypertrophic cardiomyopathy: report of a Working Group of the National Heart, Lung, and Blood Institute. Circulation 2010, 122:1130-1133.
7. Shimada YJ, Passeri JJ, Baggish AL, et al. Effects of losartan on left ventricular hypertrophy and fibrosis in patients with nonobstructive hypertrophic cardiomyopathy. JACC Heart Fail 2013, 1:480-487.
8. American College of Cardiology Foundation/American Heart Association Task Force on Practice, American Association for Thoracic Surgery, American Society of Echocardiography, et al. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Thorac Cardiovasc Surg 2011, 142:e153-e203.
9. Cannan CR, Reeder GS, Bailey KR, Melton LJ, Gersh BJ Natural history of hypertrophic cardiomyopathy. A population-based study, 1976 through 1990. Circulation 1995, 92:2488-2495.
10. Spirito P, Chiarella F, Carratino L, Berisso MZ, Bellotti P, Vecchio C Clinical course and prognosis of hypertrophic cardiomyopathy in an outpatient population. N Engl J Med 1989, 320:749-755.
11. Cecchi F, Olivotto I, Montereggi A, Santoro G, Dolara A, Maron BJ Hypertrophic cardiomyopathy in Tuscany: clinical course and outcome in an unselected regional population. J Am Coll Cardiol 1995, 26:1529-1536.
12. Maron BJ, Casey SA, Hauser RG, Aeppli DM Clinical course of hypertrophic cardiomyopathy with survival to advanced age. J Am Coll Cardiol 2003, 42:882-888.
13. Devereux RB, Dahlof B, Gerdts E, et al. Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial. Circulation 2004, 110:1456-1462.
14. Teekakirikul P, Eminaga S, Toka O, et al. Cardiac fibrosis in mice with hypertrophic cardiomyopathy is mediated by non-myocyte proliferation and requires Tgf-β. J Clin Invest 2010, 120:3520-3529.
15. Lim DS, Lutucuta S, Bachireddy P, et al. Angiotensin II blockade reverses myocardial fibrosis in a transgenic mouse model of human hypertrophic cardiomyopathy. Circulation 2001, 103:789-791.
16. Tsybouleva N, Zhang L, Chen S, et al. Aldosterone, through novel signaling proteins, is a fundamental molecular bridge between the genetic defect and the cardiac phenotype of hypertrophic cardiomyopathy. Circulation 2004, 109:1284-1291.
17. de Resende MM, Kriegel AJ, Greene AS Combined effects of low-dose spironolactone and captopril therapy in a rat model of genetic hypertrophic cardiomyopathy. J Cardiovasc Pharmacol 2006, 48:265-273.
18. Penicka M, Gregor P, Kerekes R, et al. The effects of candesartan on left ventricular hypertrophy and function in nonobstructive hypertrophic cardiomyopathy: a pilot, randomized study. J Mol Diagn 2009, 11:35-41.
19. Kawano H, Toda G, Nakamizo R, Koide Y, Seto S, Yano K Valsartan decreases type I collagen synthesis in patients with hypertrophic cardiomyopathy. Circ J 2005, 69:1244-1248.
20. Yamazaki T, Suzuki J, Shimamoto R, et al. A new therapeutic strategy for hypertrophic nonobstructive cardiomyopathy in humans. A randomized and prospective study with an angiotensin II receptor blocker. Int Heart J 2007, 48:715-724.
21. Araujo AQ, Arteaga E, Ianni BM, Buck PC, Rabello R, Mady C Effect of losartan on left ventricular diastolic function in patients with nonobstructive hypertrophic cardiomyopathy. Am J Cardiol 2005, 96:1563-1567.
22. Lang RM, Bierig M, Devereux RB, et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 2005, 18:1440-1463.
23. Jensen MK, Havndrup O, Christiansen M, et al. Penetrance of hypertrophic cardiomyopathy in children and adolescents: a 12-year follow-up study of clinical screening and predictive genetic testing. Circulation 2013, 127:48-54.
24. Spoladore R, Maron MS, D'Amato R, Camici PG, Olivotto I Pharmacological treatment options for hypertrophic cardiomyopathy: high time for evidence. Eur Heart J 2012, 33:1724-1733.
25. Hall C NT-ProBNP: the mechanism behind the marker. J Card Fail 2005, 11(5 suppl):S81-S83.
26. Thaman R, Esteban MT, Barnes S, et al. Usefulness of N-terminal pro-B-type natriuretic peptide levels to predict exercise capacity in hypertrophic cardiomyopathy. Am J Cardiol 2006, 98:515-519.
27. Saura D, Marin F, Climent V, et al. Left atrial remodelling in hypertrophic cardiomyopathy: relation with exercise capacity and biochemical markers of tissue strain and remodelling. Int J Clin Pract 2009, 63:1465-1471.
28. Todiere G, Aquaro GD, Piaggi P, et al. Progression of myocardial fibrosis assessed with cardiac magnetic resonance in hypertrophic cardiomyopathy. J Am Coll Cardiol 2012, 60:922-929.
29. Guttmann OP, Rahman MS, O'Mahony C, Anastasakis A, Elliott PM Atrial fibrillation and thromboembolism in patients with hypertrophic cardiomyopathy: systematic review. Heart 2014, 100:465-472.
30. Ho CY, Abbasi SA, Neilan TG, et al. T1 measurements identify extracellular volume expansion in hypertrophic cardiomyopathy sarcomere mutation carriers with and without left ventricular hypertrophy. Circ Cardiovasc Imaging 2013, 6:415-422.
31. Dalsgaard M, Iversen K, Kjaergaard J, et al. Short-term hemodynamic effect of angiotensin-converting enzyme inhibition in patients with severe aortic stenosis: a placebo-controlled, randomized study. Am Heart J 2014, 167:226-234.
32. Green JJ, Berger JS, Kramer CM, Salerno M Prognostic value of late gadolinium enhancement in clinical outcomes for hypertrophic cardiomyopathy. JACC Cardiovasc Imaging 2012, 5:370-377.
33. O'Mahony C, Jichi F, Pavlou M, et al. A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM Risk-SCD). Eur Heart J 2014, 35:2010-2020. for the Hypertrophic Cardiomyopathy Outcomes Investigators.
34. Spirito P, Bellone P, Harris KM, Bernabo P, Bruzzi P, Maron BJ Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy. N Engl J Med 2000, 342:1778-1785.
35. Olivotto I, Maron MS, Autore C, et al. Assessment and significance of left ventricular mass by cardiovascular magnetic resonance in hypertrophic cardiomyopathy. J Am Coll Cardiol 2008, 52:559-566.